
Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is charting rocky waters as it looks to secure a partner to advance its liver cancer drug through a Phase III trial. The US biotech’s clinical asset, amezalpat, has already demonstrated positive Phase II data, though the step to Phase …